Consensus Personalis, Inc.

Stocks

PSNL

US71535D1063

Healthcare Facilities & Services

Market Closed - Nasdaq 23:00:00 30/10/2026 +03			5-day change	1st Jan Change
15.82 ^USD	-0.66%		-0.19%	+98.74%

10-27	Alert from law firm tagged to Personalis withdrawn	RE
10-21	Personalis, Inc. Announces NeXT Personal Ultrasensitive Circulating Tumor DNA Test Presentations at ESMO Congress 2026	CI

Evolution of the Average Target: Personalis, Inc.

Evolution of the Target Price: Personalis, Inc.

Changes in Analyst Recommendations: Personalis, Inc.

3.4JI0NaecUTXgVVIEPKGD3NT81ElyKdvsjiYJCisZ0Xk.g-hTA-_pK3eqFGRRD-n5sIzJpAtDU6quxHdZOVtQvzu65l5t9KQnBoE-Aw~39da1ffa0cab724bc5085531411e8dde

Analysts' recommendations: Personalis, Inc.

10-06	BTIG Downgrades Personalis to Neutral From Buy	MT
08-24	Personalis Shares Fall After Craig-Hallum Downgrade	MT
08-24	Craig-Hallum Downgrades Personalis to Hold From Buy, Price Target is $16.25	MT
07-20	Personalis Acquisition Price Warranted by Growth Prospects, Needham Says	MT
07-20	Top Midday Decliners	MT
07-20	Needham Downgrades Personalis to Hold From Buy	MT
07-17	Needham Raises Price Target on Personalis to $17 From $12, Keeps Buy Rating	MT
05-12	Morgan Stanley Cuts Price Target on Personalis to $9 From $10, Keeps Equalweight Rating	MT
12-02	Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating	MT
05/08/25	Healthcare firm Personalis' Q2 revenue misses estimates	RE
15/05/25	Guggenheim Initiates Personalis at Buy With $6 Price Target	MT
17/03/25	Craig Hallum Initiates Coverage on Personalis With Buy Rating, $8 Price Target	MT
16/08/24	BTIG Raises Personalis' Price Target to $7 From $5.50, Buy Rating Maintained	MT
08/08/24	Needham Adjusts Personalis' PT to $5.50 From $3.50, Keeps Buy Rating	MT
30/04/24	Lake Street Starts Personalis With Buy Rating, $4 Price Target	MT
29/02/24	Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating	MT
08/11/23	Needham Cuts Price Target on Personalis to $2.30 From $7, Maintains Buy Rating	MT
09/08/23	HC Wainwright Adjusts Price Target on Personalis to $7.50 From $10, Maintains Buy Rating	MT
04/05/23	Needham Trims Price Target on Personalis to $7 From $8, Maintains Buy Rating	MT
27/02/23	Morgan Stanley Adjusts Price Target on Personalis to $5 From $11, Maintains Equal-Weight Rating	MT
24/02/23	HC Wainwright Trims Price Target on Personalis to $10 From $13, Maintains Buy Rating	MT
06/02/23	Needham Upgrades Personalis to Buy From Hold, Says Encouraged by Cost Reductions, Price Target is $8	MT
03/11/22	HC Wainwright Adjusts Personalis' Price Target to $13 From $26, Keeps Buy Rating	MT
03/11/22	Citigroup Adjusts Price Target on Personalis to $6 From $8, Maintains Buy Rating	MT
04/08/22	Citigroup Lowers Personalis' Price Target to $8 From $14, Maintains Buy Rating	MT

More recommendations

Medical & Diagnostic Laboratories

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PERSONALIS, INC.					-4.13%
	CVS HEALTH CORPORATION					+27.96%
	HCA HEALTHCARE, INC.					-0.69%
	NATERA, INC.					+0.5%
	LABCORP HOLDINGS INC.					+4.28%
	FRESENIUS SE & CO. KGAA					+18.02%
	QUEST DIAGNOSTICS INCORPORATED					+2.16%
	TENET HEALTHCARE CORPORATION					+6.2%
	DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY					+19.93%
	IHH HEALTHCARE					+31.59%
	Average					+10.58%
	Weighted average by Cap.					+11.83%